Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Intangibles (2018 - 2025)

Cytosorbents (CTSO) has disclosed Intangibles for 7 consecutive years, with $3.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Intangibles changed N/A year-over-year to $3.7 million, compared with a TTM value of $3.7 million through Jun 2025, changed N/A, and an annual FY2024 reading of $3.7 million, down 4.06% over the prior year.
  • Intangibles was $3.7 million for Q2 2025 at Cytosorbents, up from $3.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $4.7 million in Q4 2021 and bottomed at $3.7 million in Q1 2025.
  • Average Intangibles over 5 years is $4.0 million, with a median of $3.8 million recorded in 2023.
  • The sharpest move saw Intangibles increased 11.36% in 2021, then fell 11.02% in 2023.
  • Year by year, Intangibles stood at $4.7 million in 2021, then dropped by 6.62% to $4.4 million in 2022, then decreased by 11.02% to $3.9 million in 2023, then decreased by 4.06% to $3.7 million in 2024, then dropped by 0.24% to $3.7 million in 2025.
  • Business Quant data shows Intangibles for CTSO at $3.7 million in Q2 2025, $3.7 million in Q1 2025, and $3.7 million in Q4 2024.